Epivir (3TC, Lamivudine)
| Brand Name: |
Epivir |
| Generic Name: |
Lamivudine, 3TC |
| Adult Single Dose: |
One 150-mg tablet (twice a day) OR one 300-mg tablet (once a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- Lamivudine (Epivir) (November 15, 2012)
To read PDF, click here.
From AIDS InfoNet
- An Overview of Epivir (3TC, Lamivudine) (September 13, 2012)
From AIDSinfo
- Epivir (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Patient Information About Epivir (3TC, Lamivudine) (PDF) (November 2011)
From ViiV Healthcare
- Epivir (Lamivudine, 3TC) (September 28, 2008)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- 3TC (Epivir, Lamivudine) (October 26, 2006)
From AIDS Treatment Data Network
- Epivir (Lamivudine) (September 6, 2006)
To read PDF, click here.
From The Center for AIDS
- Drug Interactions: Lamivudine (August 2004)
From Project Inform
- Profiles on New Drugs (March 1996)
In Moore News for Care Providers, from Johns Hopkins AIDS Service
News
- FDA Approves Generic Formulations of Lamivudine and Zidovudine Tablets and Nevirapine Tablets and Oral Suspension (May 25, 2012)
From U.S. Food and Drug Administration
- FDA Says Merck's HIV Drug Gets Generic Threat (January 11, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Epivir Tablets for Pediatric Dosing (February 7, 2008)
From U.S. Food and Drug Administration
- Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
- WHO Approves New Generic Lamivudine, Fluconazole Pills (July 14, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- WHO Removes Cipla's Lamivudine, Zidovudine Generics From Approved Drug List (June 16, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- FDA Bits: 3TC, Amprenavir and Nandrolone (September 2002)
Once-a-day dosing for 3TC (Epivir) approved; new interaction warnings for amprenavir (Agenerase); nandrolone decanoate returns to the U.S. market.
In HIV Treatment ALERTS!, from The Center for AIDS
- Initial Therapy With d4T or 3TC Appears to Confer Survival Benefit (April 1998)
In HIV Newsline, from San Francisco General Hospital
- 3TC: Glaxo Wellcome Broadens Patient Assistance (June 7, 1996)
In AIDS Treatment News, from AIDS Treatment News
VIEW ALL ARTICLES
Research
- Dose Optimisation: 50 mg Ritonavir-Boosting, 3TC Dosing and Raltegravir Once-Daily (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From TheBodyPRO.com
- Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
- Once-Daily Abacavir + Lamivudine + Tenofovir Fails in Naive Patients (April 2005)
In Expert Opinion on Investigational Drugs, from TheBodyPRO.com
- Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- No Difference Seen in Resistance Profiles of Emtricitabine and Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Sequencing and 2 of the Most Popular Backbone Regimens (February 25, 2005)
A comparison of resistance mutations with abacavir + lamivudine versus tenofovir + lamivudine.
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Failure of Tenofovir/Abacavir/Lamivudine Combination Still Unexplained (July 13, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
